Skip to main content
Log in

Drug therapy for acquired pendular nystagmus in multiple sclerosis

  • Original communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity. Therapeutic approaches to APN remain controversial, and there is no generally accepted therapeutic approach. We tested 14 patients who had suffered from APN caused by multiple sclerosis for several years; 12 patients presented with fixational pendular nystagmus (increasing during fixation) and 2 with spontaneous pendular nystagmus. All 11 patients with fixational pendular nystagmus who were given memantine, a glutamate antagonist, experienced complete cessation of the nystagmus. In contrast, scopolamine caused no (6 of 8) or only a minor (10–50%) reduction of the nystagmus (2 of 8). It was concluded that memantine is a safe treatment option for APN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 29 August 1995 Received in revised form: 6 August 1996 Accepted: 19 August 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Starck, M., Albrecht, H., Pöllmann, W. et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 244, 9–16 (1996). https://doi.org/10.1007/PL00007728

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00007728

Navigation